FTC moves to block DNA sequencer Illumina’s acquisition of PacBio
Illumina has become dominant in next-generation sequencing by building machines that sequenced DNA cheaper and faster than others.
Related Articles
RFK Jr. presses infant formula makers on seed oils, supply chain, and contaminants
FDA will review nutrients, increase testing for heavy metals and contaminants, explore development of updated formulas.
Eric Green is out as head of National Human Genome Research Institute
The longtime director of the National Human Genome Research Institute is stepping down, as the larger NIH braces for more changes.
Return-to-office mandates pose the latest challenge to morale at the FDA
Departures of key staff from the FDA could lead to delays in inspections and product approvals.
RFK Jr.’s regenerative medicine roundtable on stem cell deregulation raises red flags
RFK Jr.’s recent roundtable on regenerative medicine offers some worrying signs about his approach to regulating stem cells.
These 12 Chinese companies are poised to transform CRISPR gene-editing
The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are the companies to know.
At NIH, ‘everyone is on edge’ as they brace for deep cuts and more centralized control
As the NIH braces for cuts of up to 5,000 of its 20,000 positions, “people are scrambling and freaking out,” a researcher said.
UMass medical school rescinds PhD program offers amid uncertainty over federal funds
The notice, signed by dean of the college, Mary Ellen Lane, called the decision “unfortunate” and said institutions across the country are “rescinding offers of…
Dr. Oz pledges Medicare Advantage scrutiny: ‘There is a new sheriff in town’
Oz mentioned risk coding and prior authorizations as areas he plans to examine in Medicare Advantage.
Mineralys Therapeutics stock soars on blood pressure drug data
Mineralys Therapeutics, a small drug developer, said its experimental drug significantly reduced blood pressure in two different studies, giving the medicine a path to market.
States push fight against mRNA vaccines
These moves risk further sowing misinformation and distrust in the technology and creating a technological divide when it comes to drugs and vaccines.